<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346397</url>
  </required_header>
  <id_info>
    <org_study_id>RSCS-Campath-06</org_study_id>
    <nct_id>NCT01346397</nct_id>
  </id_info>
  <brief_title>Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation</brief_title>
  <acronym>RSCS-Campath</acronym>
  <official_title>Prospective Randomized Trial Comparing CsA Versus Tacro After Campath Induction In Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Russian Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Russian Scientific Center of Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Russian Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After alemtuzumab induction, followed with kidney transplantation, patients will be randomly
      assigned to receive either tacrolimus or cyclosporine microemulsion in combination with
      mycophenolates. Patients will be followed including protocol biopsy at 1, 12, 36, 60 month
      posttransplant, regular nuclein acid testing (NAT) for cytomegalovirus (CMV), Epstein-Barr
      virus (EBV) and BK virus (BKV) in urine and blood.

      The investigation is undertaken to clarify the reason for equal survival rates for patients
      on cyclosporine and tacrolimus despite the lower rejection rate on tacrolimus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Special attention will be paid to the epidemiology of virus infections behind one year post
      transplant. Very limited data are available on this issue and there is suspicion that
      tacrolimus patients suffer more hard with viruses like CMV, EBV, BKV. These viruses can
      induce graft nephropathy and threat to the life of the recipient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>5 years</time_frame>
    <description>in cyclosporine group 96.4 +/- 2.8%; in tacrolimus group 96.3 +/- 3.4%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Survival</measure>
    <time_frame>5 years</time_frame>
    <description>in cyclosporine group 84.6 +/- 5.8%; in tacrolimus group 86.2 +/- 4.1%</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">170</enrollment>
  <condition>Acute Graft Rejection</condition>
  <condition>Chronic Allograft Nephropathy</condition>
  <condition>Polyomavirus-related Transplant Nephropathy</condition>
  <arm_group>
    <arm_group_label>cyclosporine group</arm_group_label>
    <description>cyclosporine group - after alemtuzumab induction cyclosporine was administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tacrolimus group</arm_group_label>
    <description>tacrolimus group - after alemtuzumab induction tacrolimus was administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine or tacrolimus</intervention_name>
    <description>after alemtuzumab, cyclosporine or tacrolimus was administered</description>
    <arm_group_label>cyclosporine group</arm_group_label>
    <arm_group_label>tacrolimus group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and urine, taken at the time of protocol or case biopsies will be deeply freeze and
      stocked for future examination for NAT or other molecules - candidates for diagnostic
      markers.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Recipients of kidney allograft who underwent previous Campath induction and do receive
        calcineurine inhibitor (CNI)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first kidney allograft recipients

          -  alemtuzumab induction

        Exclusion Criteria:

          -  CNI intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael M Kaabak, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Russian Scientific Center of Surgery RAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Research Centre of Surgery</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <results_first_submitted>October 4, 2016</results_first_submitted>
  <results_first_submitted_qc>October 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2016</results_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Russian Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Michael Kaabak</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>rejection</keyword>
  <keyword>survival</keyword>
  <keyword>alemtuzumab</keyword>
  <keyword>cyclosporine</keyword>
  <keyword>tacrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cyclosporine Group</title>
          <description>cyclosporine group - after Campath induction cyclosporine will be administered</description>
        </group>
        <group group_id="P2">
          <title>Tacrolimus Group</title>
          <description>tacrolimus group - after Campath induction tacrolimus will be administered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyclosporine Group</title>
          <description>cyclosporine group - after alemtuzumab induction cyclosporine was administered</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus Group</title>
          <description>tacrolimus group - after alemtuzumab induction tacrolimus was administered
cyclosporine or tacrolimus: after alemtuzumab, cyclosporine or tacrolimus was administered</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" spread="14"/>
                    <measurement group_id="B2" value="21" spread="15"/>
                    <measurement group_id="B3" value="20" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Deceased donor kidney transplant recipients</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Survival</title>
        <description>in cyclosporine group 96.4 +/- 2.8%; in tacrolimus group 96.3 +/- 3.4%</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine Group</title>
            <description>cyclosporine group - after alemtuzumab induction cyclosporine was administered</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Group</title>
            <description>tacrolimus group - after alemtuzumab induction tacrolimus was administered
cyclosporine or tacrolimus: after alemtuzumab, cyclosporine or tacrolimus was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival</title>
          <description>in cyclosporine group 96.4 +/- 2.8%; in tacrolimus group 96.3 +/- 3.4%</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="94" upper_limit="98.8"/>
                    <measurement group_id="O2" value="96.3" lower_limit="92.9" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Graft Survival</title>
        <description>in cyclosporine group 84.6 +/- 5.8%; in tacrolimus group 86.2 +/- 4.1%</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine Group</title>
            <description>cyclosporine group - after alemtuzumab induction cyclosporine was administered</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus Group</title>
            <description>tacrolimus group - after alemtuzumab induction tacrolimus was administered
cyclosporine or tacrolimus: after alemtuzumab, cyclosporine or tacrolimus was administered</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Survival</title>
          <description>in cyclosporine group 84.6 +/- 5.8%; in tacrolimus group 86.2 +/- 4.1%</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="78.7" upper_limit="90.5"/>
                    <measurement group_id="O2" value="86.2" lower_limit="82.6" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cyclosporine Group</title>
          <description>cyclosporine group - after alemtuzumab induction cyclosporine was administered</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus Group</title>
          <description>tacrolimus group - after alemtuzumab induction tacrolimus was administered
cyclosporine or tacrolimus: after alemtuzumab, cyclosporine or tacrolimus was administered</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>patient death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>kidney graft loss</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>clinical acute rejection</sub_title>
                <description>rejection accompanied by disturbances of the kidney graft function</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="85"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>all rejection rate, including subclinical rejections.</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="85"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Michael Kaabak</name_or_title>
      <organization>Boris Petrovsky research cener od surgery</organization>
      <phone>+74992481344</phone>
      <email>kaabak@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

